Skip to content

The value of PSMA PET in evaluating the efficacy of 223Ra in the treatment of prostate cancer

The value of PSMA PET in evaluating the efficacy of 223Ra in the treatment of prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060747
Enrollment
Unknown
Registered
2022-06-09
Start date
2022-06-01
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

Case series:None

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed metastatic castration-resistant prostate cancer; 2. Two or more bone metastases were found in the bone scan, and there was no known visceral metastasis, or there was lymph node metastasis but the minor axis diameter was less than 3cm; 3. Regardless of whether they had received docetaxel chemotherapy or not.

Exclusion criteria

Exclusion criteria: 1. Received chemotherapy or did not recover from adverse events caused by chemotherapy in the past 4 weeks; 2. Previous half-body extracorporeal radiotherapy and received whole-body radiotherapy in the past 24 weeks; 3. Blood transfusion or erythropoietin stimulant was used in the past 4 weeks; 4. Imminent or confirmed compression of the spinal cord.

Design outcomes

Primary

MeasureTime frame
Maximum standard uptake value;Progression Free Survival;

Secondary

MeasureTime frame
Objective Response Rate;Clinical benefit rate;overall survival;

Countries

China

Contacts

Public ContactShaoli Song

Fudan University Shanghai Cancer Center

shaoli-song@163.com+86 18121299622

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026